Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI Pays $25mn for Part of Teva’s Generics Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

ANI Pays $25mn for Part of Teva’s Generics Portfolio

Includes 19 solid-oral dosage products, and 3 oral suspension products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ANI Pharmaceuticals has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI’s two manufacturing facilities; these four products have a combined trailing twelve month market value of $210 million, according to IMS Health. The total market value for the 22 products is $650 million on a trailing twelve-month basis, per IMS Health.

“I am excited to add this group of approved products to our generic portfolio and to further leverage our manufacturing capabilities,” said Arthur Przybyl, president and chief executive officer, ANI Pharmaceuticals. “Importantly, we will be manufacturing one of the initial products out of our containment facility for potent compounds. This acquisition expands our product pipeline to 68 products with a total market value of $3.9bn per IMS Health.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics